Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COLGENES

Financiado

Cerrado

Defining novel mechanisms critical for colorectal tumourigenesis

Cancer genome sequencing has led to a paradigm shift in our understanding of oncogenesis. It has identified thousands of genetic alterations that segregate into two groups, a small number of frequently mutated genes and a much lar... ver más

31/01/2023

UEDIN

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-01-31

ERC-2016-STG: ERC Starting Grant Scope:Objectives

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UEDIN

1.50M€ | Lider

ZUBITRONIKA, S.L.

652.22K€ | Participante

Proyectos interesantes

Organ-VIP

Medical Technol...

Data Science

161K€ Cerrado

RTI2018-094009-B-I00

Medical Technol...

Data Science

182K€ Cerrado

SpatialOrganoids

Medical Technol...

Data Science

191K€ Cerrado

INTRAHETEROSEQ

Medical Technol...

Data Science

1M€ Cerrado

POPYNA

Medical Technol...

Data Science

Financiado

EDITCRC

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 71 meses Fecha Inicio: 2017-02-03
Fecha Fin: 2023-01-31

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer genome sequencing has led to a paradigm shift in our understanding of oncogenesis. It has identified thousands of genetic alterations that segregate into two groups, a small number of frequently mutated genes and a much larger number of infrequently mutated genes. The causative role of frequently mutated genes is often clear and are the focus of concerted therapeutic development efforts. The role of those infrequently mutated is often unclear and can be difficult to separate from ‘mutational noise’. Determining the relevance of low frequency mutations is important for providing a full understanding of processes driving tumourigenesis and if functionally relevant may have broader implications on the applicability of targeted therapies. This project aims to begin addressing this by defining the function of all genes mutated in colorectal cancer (CRC) in the earliest stages of tumour formation. I have performed a whole genome screen in a 3D organoid CRC initiation model identifying several potentially important mediators of this process. Crucially, some of these genes are mutated in CRC at low frequency but not described as cancer driver genes. Thus, I hypothesize that rather than ‘mutational noise’ infrequently mutated genes contribute to CRC initiation. I will test this by addressing two aims: 1) Determine the role of genes mutated in CRC during tumour initiation 2) Validate and determine the function of a subset of identified genes potentially defining novel cancer mechanisms I will use a combination of CRISPR genetic disruption in state-of-the-art 3D mouse and human organoid cultures and advanced mouse models to address these aims. This comprehensive approach will provide a foundation for understanding the importance of the entire spectrum of mutations in CRC and open new avenues of research into the function of these genes. More broadly, it has the potential to make a profound impact on how we think about tumourigenic mechanisms and cancer therapeutics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores